Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cellsâ€™ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
06/26/06	$0.8000	-8.04%	1,01,024
04/26/04	$0.8699	-3.67%	66,608
03/26/03	$0.9030	+2.61%	33,699
02/26/02	$0.8800	+2.33%	29,820
30/26/30	$0.8600	-0.30%	66,661

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8699USD

Average target price

14.00USD

Spread / Average Target

+1,509.38%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Phio Pharmaceuticals Corp.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Phio Pharmaceuticals Corp.

Company calendar

Real-time Estimate Cboe BZX 01:42:36 06/11/2026 am IST			5-day change	1st Jan Change
0.7930 ^USD	-8.84%		-7.26%	-23.81%

13/10	Phio Pharmaceuticals Corp. Announces Successful Completion of First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance	CI
14/09	Phio Pharmaceuticals Corp Submits Materials To FDA Supporting Next Stage Of Clinical Development For PH-762 In Cutaneous Squamous Cell Carcinoma	CI

Market Cap	1.01Cr 90.05L 82.37L 75.02L 1.41Cr 96Cr 1.45Cr 9.9Cr 3.96Cr 51Cr 3.79Cr 3.71Cr 159.6Cr	P/E 2026 *	-0.6x	P/E 2027 *	-1.43x
Enterprise Value	1.01Cr 90.05L 82.37L 75.02L 1.41Cr 96Cr 1.45Cr 9.9Cr 3.96Cr 51Cr 3.79Cr 3.71Cr 159.6Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	91.99%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	PHIO	Delayed
CBOE	PHIO	Real-time

13/10	Phio Pharmaceuticals Corp. Announces Successful Completion of First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance	CI
14/09	Phio Pharmaceuticals Corp Submits Materials To FDA Supporting Next Stage Of Clinical Development For PH-762 In Cutaneous Squamous Cell Carcinoma	CI
07/08	Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
21/07	Phio Pharmaceuticals Corp. Appoints R. Todd Plott to its Board and Governance Committee, Effective July 20, 2026	CI
15/07	Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision	CI
24/06	Phio Pharmaceuticals Corp. Announces the Manufacture of the First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance Has Commenced At Nitto Denko Avecia, Inc	CI
08/05	Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
09/04	Phio Pharmaceuticals Corp - Enters at the Market Offering Agreement with H.C. Wainwright on April 8, 2026	RE
30/03	Phio Pharmaceuticals Corp Announces Agreement With U.S. cGMP Manufacturing Source For Drug Product PH-762	CI
06/03	Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/02	Phio Pharmaceuticals Corp. Promotes Jennifer Phillips, Pharm.D., to Senior Vice President	CI
10/02	Phio Pharmaceuticals Corp. Announces Safety Monitoring Committee's Positive Wrap-Up on Lead Clinical Candidate PH-762 in Skin Cancer Trial	CI
20/01	Phio Pharmaceuticals Corp announces key tumor response data from PH-762 trial	RE

Phio Pharmaceuticals Corp. Share Price

Stocks

PHIO

US71880W5013

Biotechnology & Medical Research

Valuation: Phio Pharmaceuticals Corp.

Chart: Phio Pharmaceuticals Corp.

Latest news: Phio Pharmaceuticals Corp.

Analysts' recommendations: Phio Pharmaceuticals Corp.

Press Releases: Phio Pharmaceuticals Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Phio Pharmaceuticals Corp.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

31/25/31	Phio Pharmaceuticals Corp. Announces Resignation of Robert Ferrara as Lead Independent Director of the Board and Compensation Committee and the Audit Committee, Effective October 31, 2025	CI
06/24/06	HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating	MT
14/21/14	Phio Pharmaceuticals : HC Wainwright Adjusts Phio Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating	MT

19/10	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE
13/10	Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance	NE
06/10	Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026	NE
05/10	Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference	NE
23/09	Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference	NE

1 day	-8.84%
1 week	-7.26%
Current month	-6.98%
1 month	-19.27%
3 months	-25.23%
6 months	-29.20%
Current year	-23.81%

1 week	0.8	0.92
1 month	0.8	1.02
Current year	0.8	1.88
1 year	0.8	1.88
3 years	0.8	18.81
5 years	0.8	261.36
10 years	0.8	1,74,042.17

Manager	Title	Age	Since
Robert Bitterman CEO	Chief Executive Officer	75	-
Lisa Carson DFI	Director of Finance/CFO	60	12/05/2025
Mary Spellman CTO	Chief Tech/Sci/R&D Officer	64	-

Director	Title	Age	Since
Robert Bitterman CHM	Chairman	75	30/04/2013
Curtis Lockshin BRD	Director/Board Member	65	18/04/2013
Jonathan Freeman BRD	Director/Board Member	58	07/06/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/09/26	R. Plott	Buy	Director	5,000	0.0430%
28/09/26	Lisa Carson	Free	Chief Financial Officer	1,08,000	0.9297%
28/09/26	Robert Bitterman	Free	Chief Executive Officer	4,00,000	3.4432%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHIO PHARMACEUTICALS CORP.	-8.84%	-7.26%	-49.37%	-92.71%	1.01Cr
WUXI APPTEC CO., LTD.	+3.80%	+8.47%	+64.65%	+77.70%	6.69TCr
LONZA GROUP AG	+1.63%	+4.93%	+24.89%	+102.90%	5.65TCr
ARGENX SE	+0.07%	+1.39%	+12.75%	+76.61%	5.72TCr
IQVIA HOLDINGS INC.	-0.01%	-3.56%	+26.25%	+33.71%	4.35TCr
REVOLUTION MEDICINES, INC.	-9.59%	-3.30%	+210.08%	+754.22%	4.28TCr
BEONE MEDICINES AG	+2.85%	+5.41%	+21.87%	+99.69%	4.3TCr
GENMAB A/S	+1.59%	-4.04%	+97.66%	+81.57%	3.21TCr
CELLTRION, INC.	+7.50%	+13.28%	+28.05%	+64.46%	3.4TCr
INSMED INCORPORATED	-2.44%	-3.37%	-42.30%	+352.31%	2.41TCr
Average	-0.31%	+3.07%	+39.45%	+155.05%	4TCr
Weighted average by Cap.	+0.81%	+3.91%	+51.49%	+166.80%

	2026 *	2027 *
Net sales	-	-
Net income	-1.7Cr -1.51Cr -1.39Cr -1.26Cr -2.38Cr -160.6Cr -2.44Cr -17Cr -6.65Cr -85Cr -6.38Cr -6.24Cr -268.39Cr	-1.66Cr -1.48Cr -1.35Cr -1.23Cr -2.32Cr -156.52Cr -2.38Cr -16Cr -6.49Cr -83Cr -6.22Cr -6.08Cr -261.57Cr
Net Debt	-	-